Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tetrabenazine | The risk or severity of adverse effects can be increased when Clebopride is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Clebopride is combined with Deutetrabenazine. |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clebopride. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clebopride. |
| Levodopa | The therapeutic efficacy of Levodopa can be decreased when used in combination with Clebopride. |
| Rotigotine | The therapeutic efficacy of Rotigotine can be decreased when used in combination with Clebopride. |
| Piribedil | The therapeutic efficacy of Piribedil can be decreased when used in combination with Clebopride. |
| Cabergoline | The therapeutic efficacy of Cabergoline can be decreased when used in combination with Clebopride. |
| Dihydroergotamine | The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Clebopride. |
| Lisuride | The therapeutic efficacy of Lisuride can be decreased when used in combination with Clebopride. |
| Fenoldopam | The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Clebopride. |
| Ergoloid mesylate | The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Clebopride. |
| Pergolide | The therapeutic efficacy of Pergolide can be decreased when used in combination with Clebopride. |
| Aripiprazole | The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Clebopride. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Clebopride. |
| Brexpiprazole | The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Clebopride. |
| Dihydroergocornine | The therapeutic efficacy of Dihydroergocornine can be decreased when used in combination with Clebopride. |
| Dopexamine | The therapeutic efficacy of Dopexamine can be decreased when used in combination with Clebopride. |
| Dihydrexidine | The therapeutic efficacy of Dihydrexidine can be decreased when used in combination with Clebopride. |
| Dihydroergocryptine | The therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Clebopride. |
| Metergoline | The therapeutic efficacy of Metergoline can be decreased when used in combination with Clebopride. |
| Ropinirole | The therapeutic efficacy of Ropinirole can be decreased when used in combination with Clebopride. |
| Benzatropine | The risk or severity of adverse effects can be increased when Clebopride is combined with Benzatropine. |
| Pramipexole | The therapeutic efficacy of Pramipexole can be decreased when used in combination with Clebopride. |
| Epicriptine | The therapeutic efficacy of Epicriptine can be decreased when used in combination with Clebopride. |